ConductScience.org, home

Paper39273237

Phase I-IV Drug Trials on Hepatocellular Carcinoma in Asian Populations: A Systematic Review of Ten Years of Studies.

Raghav A and 1 other. Int J Mol Sci, 2024. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Phase I-IV Drug Trials on Hepatocellular Carcinoma in Asian Populations: A Systematic Review of Ten Years of Studies. Papers, record 39273237. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39273237

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Phase I-IV Drug Trials on Hepatocellular Carcinoma in Asian Populations: A Systematic Review of Ten Years of Studies.
PubMed
Journal
Int J Mol Sci
PubMed
Year
2024
PubMed
Publication types
Journal Article, Systematic Review
PubMed
Citations, by iCite
2
iCite
Relative citation ratio, by iCite
0.38, provisional
iCite
Revised in PubMed
2024-09-19
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Raghav AAlokhttps://orcid.org/0000-0002-2161-0604
2Jeong GBGoo Bohttps://orcid.org/0000-0003-3844-2368

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, HepatocellularMajor topic
Liver NeoplasmsMajor topic
Humans
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Asian People
Bevacizumab
Phenylurea Compounds
Quinolines
Randomized Controlled Trials as Topic
Sorafenib
Clinical Trials as Topic

Source PubMed

Download CSV of topics

References102

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
121354226Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.J Hepatol2011https://conductscience.org/library/papers/21354226PubMed
214667750Hepatocellular carcinoma.Lancet2003https://conductscience.org/library/papers/14667750PubMed
323980090Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.J Clin Oncol2013https://conductscience.org/library/papers/23980090PubMed
430843325Diagnostic and prognostic biomarkers in cholangiocarcinoma.Liver Int2019https://conductscience.org/library/papers/30843325PubMed
518650514Sorafenib in advanced hepatocellular carcinoma.N Engl J Med2008https://conductscience.org/library/papers/18650514PubMed
630665869Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol2019https://conductscience.org/library/papers/30665869PubMed
718852116Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther2008https://conductscience.org/library/papers/18852116PubMed
833087333Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial.Clin Cancer Res2021https://conductscience.org/library/papers/33087333PubMed
925294897A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.Clin Cancer Res2014https://conductscience.org/library/papers/25294897PubMed
1034087115Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.Lancet Gastroenterol Hepatol2021https://conductscience.org/library/papers/34087115PubMed
1134914889Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.Lancet Oncol2022https://conductscience.org/library/papers/34914889PubMed
1236353563Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: A retrospective analysis.Front Oncol2022https://conductscience.org/library/papers/36353563PubMed
1331024205Hepatocellular Carcinoma: Etiology and Current and Future Drugs.J Clin Exp Hepatol2019https://conductscience.org/library/papers/31024205PubMed
14310601202018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.Gut Liver2019https://conductscience.org/library/papers/31060120PubMed
1534902530Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.J Hepatol2022https://conductscience.org/library/papers/34902530PubMed
1623340295Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide.Clin Cancer Res2013https://conductscience.org/library/papers/23340295PubMed
1719095497Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.Lancet Oncol2009https://conductscience.org/library/papers/19095497PubMed
1832847838Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial.ESMO Open2020https://conductscience.org/library/papers/32847838PubMed
1921399234Recent advances in anti-angiogenic therapy of cancer.Oncotarget2011https://conductscience.org/library/papers/21399234PubMed
2028434648Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.Lancet2017https://conductscience.org/library/papers/28434648PubMed

See all 102 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42639780
Efficacy and safety of Heshu Xiaoji pills combined with standard treatment strategy in hepatitis B virus-related hepatocellular carcinoma: a single-center, open-label, prospective controlled, real-world cohort study.
J Tradit Chin Med2026https://conductscience.org/library/papers/42639780PubMed
40647587Drug-Induced Autoimmune Hepatitis: Robust Causality Assessment Using Two Different Validated and Scoring Diagnostic Algorithms.Diagnostics (Basel)2025https://conductscience.org/library/papers/40647587PubMed
39781529The Red Cell Distribution Width to Albumin Ratio: A Novel Prognostic Indicator in Hepatitis B Virus-Related Hepatocellular Carcinoma.Int J Med Sci2025https://conductscience.org/library/papers/39781529PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39273237

GET https://conductscience.org/api/papers/v1/39273237/references?page=2